Trial
NCT02627820
The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Brigham and Women's Hospital
Collaborators
GlaxoSmithKline; Ionis Pharmaceuticals, Inc.
Condition
Amyloidosis
Intervention
Isis 420915/GSK 299872
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-08-10